Home › Companies › Viking Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Viking Therapeutics, Inc.’s Form 8-K, filed May 26, 2026 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of May 19, 2026: 4 items on Viking Therapeutics, Inc.’s Form 8-K, filed May 26, 2026: 2 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Viking Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Viking Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 26, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: J. Matthew Singleton | 28,648,459 | -- | -- | 14,562,012 | 36,879,061 | 66% | Not verified | — |
| Elect Director: S. Kathryn Rouan, Ph.D. | 21,960,203 | -- | -- | 21,250,268 | 36,879,061 | 50.8% | Not verified | — |
| 2. To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 | 78,368,957 | 1,241,969 | 478,606 | -- | -- | 98% | Approved | — |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement | 30,045,938 | 12,763,135 | 401,396 | -- | 36,879,063 | 70% | Approved | — |
Source: Viking Therapeutics, Inc., Form 8-K, filed with the SEC on May 26, 2026 — read the filing on EDGAR.
Each item below shows how the 408 asset managers that disclosed a Viking Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTOR NOMINEES FOR CLASS II (term to expire in 2029): J. Matthew Singleton
Viking Therapeutics, Inc.’s own tally for this item (“Elect Director: J. Matthew Singleton”): 28,648,459 for, 14,562,012 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 13,684,558 for, 6,813,572 withheld, 499,807 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,645,406 | 0 | 80 | 6,778 | For |
| Fidelity | 1,700,563 | 0 | 0 | 4,362,187 | Mixed |
| American Century | 0 | 0 | 0 | 937,561 | Withhold |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 335,565 | 0 | 329,291 | 0 | Mixed |
| Delaware/Macquarie | 0 | 0 | 0 | 330,100 | Withhold |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 280,964 | Withhold |
| State Street | 190,298 | 0 | 0 | 225 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 147,262 | Withhold |
| Jackson National | 53,776 | 0 | 60,430 | 0 | Mixed |
| First Trust | 0 | 0 | 0 | 106,325 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 100,464 | Withhold |
| BARON SELECT FUNDS | 0 | 0 | 0 | 74,811 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 5,873 | 0 | 64,349 | 0 | Mixed |
| Victory Capital | 0 | 0 | 0 | 69,566 | Withhold |
| ProShares | 0 | 0 | 0 | 56,862 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 50,800 | Withhold |
| Columbia Threadneedle | 48,490 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 0 | 0 | 0 | 47,000 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 42,460 | Withhold |
| Guggenheim | 0 | 0 | 0 | 33,569 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 31,034 | Withhold |
Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.
Combines 9 wordings of this item as funds reported it.
50.8% Majority: yes · of votes cast
Description as filed by funds: ELECTION OF DIRECTOR NOMINEES FOR CLASS II (term to expire in 2029): S. Kathryn Rouan, Ph.D.
Viking Therapeutics, Inc.’s own tally for this item (“Elect Director: S. Kathryn Rouan, Ph.D.”): 21,960,203 for, 21,250,268 withheld, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 50.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 77 asset managers below reported 12,282,280 for, 7,807,972 withheld, 907,684 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,201,249 | 0 | 112 | 450,903 | For |
| Fidelity | 1,644,087 | 0 | 0 | 4,418,663 | Mixed |
| American Century | 0 | 0 | 0 | 937,561 | Withhold |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 664,856 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 0 | 330,100 | Withhold |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 280,964 | Withhold |
| State Street | 390 | 0 | 0 | 190,133 | Withhold |
| TIAA | 0 | 0 | 0 | 184,547 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 147,262 | Withhold |
| Jackson National | 0 | 0 | 114,206 | 0 | Abstain |
| First Trust | 0 | 0 | 0 | 106,325 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 100,464 | Withhold |
| BARON SELECT FUNDS | 0 | 0 | 0 | 74,811 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 70,222 | 0 | Abstain |
| Victory Capital | 0 | 0 | 0 | 69,566 | Withhold |
| ProShares | 0 | 0 | 0 | 56,862 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 50,800 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 48,490 | Withhold |
| Erste Asset Management GmbH | 0 | 0 | 0 | 47,000 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 42,460 | Withhold |
| Guggenheim | 0 | 0 | 0 | 33,569 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 31,034 | Withhold |
Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.
Combines 16 wordings of this item as funds reported it.
70% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.
Viking Therapeutics, Inc.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 30,045,938 for, 12,763,135 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “As a result, the Company's stockholders voted to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Viking Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “SAY ON PAY” (2 managers, 158 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,188,385 | 463,877 | 2 | 0 | For |
| Fidelity | 6,013,895 | 48,855 | 0 | 0 | For |
| American Century | 0 | 937,561 | 0 | 0 | Against |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 335,565 | 329,291 | 0 | 0 | Mixed |
| Delaware/Macquarie | 0 | 330,100 | 0 | 0 | Against |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 280,964 | 0 | 0 | 0 | For |
| State Street | 190,037 | 486 | 0 | 0 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 147,262 | 0 | 0 | Against |
| Jackson National | 53,776 | 60,430 | 0 | 0 | Mixed |
| First Trust | 0 | 106,325 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 100,464 | 0 | 0 | Against |
| BARON SELECT FUNDS | 0 | 74,811 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 5,873 | 64,349 | 0 | 0 | Mixed |
| Victory Capital | 0 | 69,566 | 0 | 0 | Against |
| ProShares | 0 | 56,862 | 0 | 0 | Against |
| WESMARK FUNDS | 0 | 50,800 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 48,490 | 0 | 0 | Against |
| RMB INVESTORS TRUST | 0 | 42,460 | 0 | 0 | Against |
| Guggenheim | 0 | 33,569 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 31,034 | 0 | 0 | Against |
| SEI | 25,312 | 1,379 | 0 | 0 | Mixed |
Fund voting reports, all 76 managers: 17,794,959 for, 3,155,829 against, 3,790 abstained, 3 not voted. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 4,876,698 | 0 | 0 | 0 | For |
| BlackRock | 924,366 | 1,829,343 | 0 | 0 | Mixed |
| GEODE CAPITAL MANAGEMENT, LLC | 1,766,786 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 0 | 1,589,304 | 0 | 0 | Against |
| American Century | 0 | 1,126,245 | 0 | 0 | Against |
| State Street | 876,021 | 10,862 | 0 | 0 | For |
| Vanguard | 856,910 | 11,279 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 822,250 | 0 | 0 | 0 | For |
| Charles Schwab | 719,637 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 654,294 | 0 | 0 | Against |
| Vestal Point Capital, LP | 0 | 583,407 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 0 | 444,781 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 394,919 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 372,352 | 0 | 0 | Against |
| Citadel | 349,253 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 0 | 336,101 | 0 | 0 | Against |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 0 | 330,100 | 0 | 0 | Against |
| WASATCH ADVISORS LP | 312,187 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 294,587 | 0 | 0 | Against |
| DE Shaw | 0 | 278,647 | 0 | 0 | Against |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 265,442 | 0 | 0 | Against |
| RBC Dominion Securities Inc. | 0 | 228,840 | 0 | 0 | Against |
| RBC Capital Markets, LLC | 0 | 210,558 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 203,187 | 0 | 0 | Against |
| Nuveen | 199,940 | 0 | 0 | 0 | For |
Institutional-manager reports, all 347 managers: 13,955,785 for, 10,693,580 against, 22,350 abstained, 505 not voted. Showing the 25 largest; see all in the interactive database.
Combines 5 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF CBIZ CPAS P.C. AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Viking Therapeutics, Inc.’s own tally for this item (“2. To ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026”): 78,368,957 for, 1,241,969 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “As a result, the Company's stockholders voted to ratify the selection of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 20,987,118 for, 8,219 against, 3,789 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,652,260 | 2 | 1 | 0 | For |
| Fidelity | 6,062,750 | 0 | 0 | 0 | For |
| American Century | 937,561 | 0 | 0 | 0 | For |
| Charles Schwab | 707,169 | 0 | 0 | 0 | For |
| BlackRock | 664,856 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 330,100 | 0 | 0 | 0 | For |
| JPMorgan | 312,705 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 305,414 | 0 | 0 | 0 | For |
| Principal | 280,964 | 0 | 0 | 0 | For |
| State Street | 190,515 | 8 | 0 | 0 | For |
| TIAA | 184,547 | 0 | 0 | 0 | For |
| Lincoln Financial | 147,262 | 0 | 0 | 0 | For |
| Jackson National | 114,206 | 0 | 0 | 0 | For |
| First Trust | 106,325 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 100,464 | 0 | 0 | 0 | For |
| BARON SELECT FUNDS | 74,811 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,222 | 0 | 0 | 0 | For |
| Victory Capital | 69,566 | 0 | 0 | 0 | For |
| ProShares | 56,862 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 50,800 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 48,490 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 47,000 | 0 | 0 | 0 | For |
| RMB INVESTORS TRUST | 42,460 | 0 | 0 | 0 | For |
| Guggenheim | 33,569 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 31,034 | 0 | 0 | 0 | For |
Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 116,105,643 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.31% |
| 2 | Fidelity | 5.22% |
| 3 | American Century | 0.81% |
| 4 | Charles Schwab | 0.61% |
| 5 | BlackRock | 0.57% |
| 6 | Delaware/Macquarie | 0.28% |
| 7 | JPMorgan | 0.27% |
| 8 | WASATCH FUNDS TRUST | 0.26% |
| 9 | Principal | 0.24% |
| 10 | State Street | 0.16% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 4.20% |
| 2 | BlackRock | 2.37% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 1.52% |
| 4 | AMERIPRISE FINANCIAL INC | 1.37% |
| 5 | American Century | 0.97% |
| 6 | State Street | 0.76% |
| 7 | Vanguard | 0.75% |
| 8 | PNC BANK, NATIONAL ASSOCIATION | 0.71% |
| 9 | Charles Schwab | 0.62% |
| 10 | PICTET ASSET MANAGEMENT SA | 0.56% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 8.60% | 13F |
| BlackRock | 5.93% | 13F |
| FMR (Fidelity) | 5.19% | 13F |
| FMR LLC | 4.97% | DEF14A |
| Two Sigma | 3.82% | 13F |
| State Street | 3.79% | 13F |
| Brian Lian, Ph.D. | 3.57% | DEF14A |
| Morgan Stanley | 2.65% | 13F |
| Citadel Advisors | 2.25% | 13F |
| D.E. Shaw | 1.44% | 13F |
Percentages above are of 116,105,643 shares outstanding, as reported by Viking Therapeutics, Inc. on its Form 10-Q dated April 15, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Viking Therapeutics, Inc.’s 10-Q dated April 15, 2026. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At Viking Therapeutics, Inc.'s shareholder meeting held May 19, 2026, in the 2025-2026 proxy season, 408 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,609 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — Viking Therapeutics, Inc.'s filing reports the proposal as approved, with 70% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Viking Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 26, 2026.
Viking Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.